Please wait while the formulary information is being retrieved.
OXERVATE (cenegermin-bkbj)
- Neurotrophic keratitis
0.002 % eye drops
- Instill 1 drop into affected eye(s) by ophthalmic route every 2 hours6 times per day for 8 weeks
Neurotrophic keratitis
- Instill 1 drop into both eyes by ophthalmic route every 2 hours 6 times per day
- Instill 1 drop into both eyes by ophthalmic route every 2 hours 6 times per day for 8 weeks
- Instill 1 drop into left eye by ophthalmic route every 2 hours 6 times per day
- Instill 1 drop into left eye by ophthalmic route every 2 hours 6 times per day for 8 weeks
- Instill 1 drop into right eye by ophthalmic route every 2 hours 6 times per day
- Instill 1 drop into right eye by ophthalmic route every 2 hours 6 times per day for 8 weeks
- Instill 1 drop into affected eye(s) by ophthalmic route every 2 hours6 times per day
- Instill 1 drop into affected eye(s) by ophthalmic route every 2 hours6 times per day for 8 weeks
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
OXERVATE (cenegermin-bkbj)
- Neurotrophic keratitis
- None
- Eye tearing
- Ocular inflammation
- Ocular pain
More Frequent
Severe
Less Severe
- None
- Conjunctival hyperemia
- Corneal deposits
- Foreign body sensation of eye
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- None
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Cenegermin-bkbj
Safety and effectiveness have not been established in ages < 2 years.
- 1 Day – 2 Years
- Safety and effectiveness have not been established in ages < 2 years.
Cenegermin-bkbj
- Severity Level:
2
- Additional Notes: Insufficient human data available. extent of systemic absorption unknown.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Cenegermin-bkbj
Insufficient human data available. extent of systemic absorption unknown.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available. extent of systemic absorption unknown. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Neurotrophic keratitis | |
| H16.23 | Neurotrophic keratoconjunctivitis |
| H16.231 | Neurotrophic keratoconjunctivitis, right eye |
| H16.232 | Neurotrophic keratoconjunctivitis, left eye |
| H16.233 | Neurotrophic keratoconjunctivitis, bilateral |
| H16.239 | Neurotrophic keratoconjunctivitis, unspecified eye |
| 0-9 | A-Z |
|---|---|
| H16.23 | Neurotrophic keratoconjunctivitis |
| H16.231 | Neurotrophic keratoconjunctivitis, right eye |
| H16.232 | Neurotrophic keratoconjunctivitis, left eye |
| H16.233 | Neurotrophic keratoconjunctivitis, bilateral |
| H16.239 | Neurotrophic keratoconjunctivitis, unspecified eye |
Formulary Reference Tool